We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives.
- Authors
Roccuzzo, Gabriele; Giordano, Silvia; Fava, Paolo; Pileri, Alessandro; Guglielmo, Alba; Tonella, Luca; Sanlorenzo, Martina; Ribero, Simone; Fierro, Maria Teresa; Quaglino, Pietro
- Abstract
Primary cutaneous T-cell lymphomas (PCTCL) are the most common types of cutaneous lymphomas, with Mycosis fungoides as the most frequent subtype. Besides early stages which usually have a good prognosis, advanced stages remain a great therapeutic challenge with low survival rates. To date, none of the currently available therapeutic options have significantly improved the outcomes of advanced cutaneous lymphomas. Recent studies have demonstrated that immune-checkpoint molecules, such as PD-1 and CTLA-4, play part in the proliferation pathways of neoplastic T-cells, as well as in other tumors. Hence, the potential role of immune-checkpoint-inhibitors in treating cutaneous lymphomas has been investigated in the last years. Herein, we outline the current knowledge regarding the role of immune-checkpoint molecules in PCTCL, their signaling pathways, microenvironment and therapeutic inhibition rationale. Moreover, we review the published data on immunotherapies in PCTCL and summarize the currently ongoing clinical trials in this field.
- Subjects
CHECK Point Software Technologies Ltd.; IMMUNE checkpoint inhibitors; IMMUNE checkpoint proteins; LYMPHOMAS; MYCOSIS fungoides; SURVIVAL rate
- Publication
Frontiers in Oncology, 2021, Vol 11, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2021.733770